愛爾眼科(300015.SZ):約1791.12萬股限制性股票6月30日解禁
格隆匯 6 月 23日丨愛爾眼科(300015.SZ)公佈,此次申請解鎖的限制性股票數量為約1791.12萬股,佔公司總股本的比例為0.4448%。
其中,符合首次授予限制性股票第四期解鎖條件的激勵對象1424人,已授予未解鎖的限制性股票數量為約1571.13萬股,申請解鎖的股份數量共計約1571.13萬股,佔公司目前股本總額的0.3901%;符合預留授予限制性股票第二期解鎖條件的激勵對象284人,已授予未解鎖的限制性股票數量為約219.99萬股,申請解鎖的股份數量共計約219.99萬股,佔公司目前股本總額的0.0546%。此次解鎖實際可上市流通的限制性股票數量為約1723.23萬股,佔公司總股本的比例為0.4279%。
此次解鎖的限制性股票上市流通日為2020年6月30日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.